Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01125553 · ClinicalTrials.gov registry record · Phase 1
A Comparison Between Two Formulations of NN5401 in Healthy Subjects
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01125553 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 26 participants.
The verdict
NCT01125553, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to compare the exposure of two formulations of insulin degludec/insulin aspart (NN5401) in healthy subjects.
Interventions
- DRUG insulin degludec/insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01125553
The ClinicalTrials.gov registry entry for NCT01125553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin degludec/insulin aspart is the first listed.
NCT01125553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01125553 about?
NCT01125553 is a clinical study titled "A Comparison Between Two Formulations of NN5401 in Healthy Subjects". This trial is conducted in the United States of America (USA). The aim of the trial is to compare the exposure of two formulations of insulin degludec/insulin aspart (NN5401) in healthy subjects.
What is the current status of trial NCT01125553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01125553?
The interventions under investigation include: insulin degludec/insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01125553?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.